Oncology Nursing News: The Vitals

By: Oncology Nursing News: The Vitals
Listen for free

  • Summary

  • The Vitals is a twice monthly podcast that discusses all things oncology nursing, from the latest clinical updates to hot topics that are on the minds of nurses across the country.
    Show More Show Less
Hygiene & Healthy Living Physical Illness & Disease Science
Show More Show Less
Episodes
  • S5 Ep80: What New Cancer Drugs Were Approved in 2023?

    S5 Ep80: What New Cancer Drugs Were Approved in 2023?
    Jan 1 2024
    In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals. Listen as editor, Lindsay Fischer, recounts key approvals on a month-by-month basis. To read the full information surrounding the approvals, be sure to check out our news coverage below.  As always, thank you for listening to The Vitals, and for all the engagement in 2023. We look forward to bringing you more oncology news in 2024. We want to hear from you! Which drugs approved in 2023 have been practice changing? Have you had any difficulty or success in incorporating these novel agents into clinical use? Any challenges with supporting patients on these regimens? Email ONNeditors@mjhlifesciences.com with your feedback January  Tucatinib and Trastuzumab Combination Gains FDA Approval for RAS Wild-Type HER2+ mCRCFDA Approves Zanubrutinib for CLL/SLLAdjuvant Pembrolizumab Gets FDA Approval in NSCLC FDA Grants Pirtobrutinib Accelerated Approval for Relapsed/Refractory MCL  February  Sacituzumab Govitecan Receives Indication for Unresectable, Locally Advanced or Metastatic HR+/HER2- Breast CancerFDA Grants Regular Approval to Dostarlimab for dMMR Endometrial Cancer March  Abemaciclib Indication Expands to Include HR+, HER2–, Node+, High-Risk, Early Breast CancerFDA Approves Single-Dose Autoinjector of Biosimilar Pegfilgrastim-cbqv for Febrile NeutropeniaFDA Approves Dabrafenib With Trametinib for Pediatric BRAF V600E–Mutant Low-Grade GliomaFDA Grants Accelerated Approval to Retifanlimab for Locally Advanced Merkel Cell CarcinomaPembrolizumab Receives Full FDA Approval for Treatment of Select Patients With dMMR/MSI-H Solid Tumors April FDA Grants Accelerated Approval to Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial CancerOmidubicel-onlv Gets Greenlight to Accelerate Neutrophil Recovery After Stem Cell Transplant in Hematologic MalignanciesPolatuzumab Vedotin Approved in Combination With R-CHP for Treatment-Naïve DLBCL, High-Grade B-Cell Lymphoma May Cemiplimab Granted Full Approval for Metastatic Basal Cell CarcinomaEpcoritamab Obtains Accelerated Approval for Relapsed/Refractory DLBCLFDA Greenlights Avapritinib for Indolent Systemic MastocytosisFDA Approves Radiohybrid PET Diagnostic Agent Posluma for PSMA-Positive Lesions in Prostate CancerOlaparib Gains FDA Approval for BRCA+ mCRPC June Glofitamab Gains Accelerated Approval for Relapsed/Refractory DLBCLFDA Approves Talazoparib in Combination With Enzalutamide for mCRPCBlinatumomab Receives Full Approval for MRD-Positive B-Cell ALL July  Ready-to-Dilute Cyclophosphamide Injections Obtain FDA ApprovalQuizartinib Plus Chemo Gains FDA Approval for Newly Diagnosed, FLT3-ITD+ AMLFDA Approves Frontline Dostarlimab in Combination With Chemotherapy for dMMR/MSI-H Endometrial Cancer August  FDA Approves Trifluridine/Tipiracil With Bevacizumab for Metastatic Colorectal CancerPralsetinib Gains Regular Approval for NSCLC With RET Gene FusionsTalquetamab Receives Accelerated Approval for Heavily Pretreated Multiple MyelomaFDA Approves Niraparib Plus Abiraterone Acetate to Treat BRCA+ mCRPCFDA Grants Elranatamab Accelerated Approval for Relapsed or Refractory Multiple MyelomaFDA Approves Hepzato Kit for Metastatic Uveal Melanoma With Liver Metastases September FDA Approves Motixafortide Plus G-CSF to Mobilize Hematopoietic Stem Cells in Multiple MyelomaFDA Approves Momelotinib to Treat Myelofibrosis With AnemiaBosutinib Is Approved for Pediatric Ph+ CP–Chronic Myeloid Leukemia October  FDA Grants Marketing Authorization to First DNA Test to Assess Multiple Cancer PredispositionsFDA Approves Encorafenib/Binimetinib for BRAF V600E+ NSCLCFDA Approves Adjuvant Nivolumab for Stage IIB/C MelanomaPembrolizumab/Chemotherapy is Approved for Neoadjuvant and Adjuvant Resectable Non-Small Cell Lung CancerEntrectinib Is Approved for Pediatric Patients With NTRK+ Solid TumorsFDA Approves Ivosidenib to Treat Myelodysplastic Syndromes With IDH1 MutationFDA Approves Toripalimab Regimens to Treat Adults With Nasopharyngeal Carcinoma November  FDA Grants Pembrolizumab New Biliary Tract Cancer IndicationFDA Approves Fruquintinib for Patients With Pretreated Metastatic Colorectal CancerFDA Approves Repotrectinib for Adults With Advanced/Metastatic ROS1+ NSCLCPembrolizumab Is Approved for Patients With HER2– Gastric/GEJ AdenocarcinomaFDA Approves Capivasertib/Fulvestrant for Advanced/Metastatic, HR+, HER2- Breast CancerFDA Approves Enzalutamide for High-Risk Nonmetastatic Castration-Sensitive Prostate CancerFDA OKs Nirogacestat for Adults Patients With Desmoid Tumors December FDA Grants Pirtobrutinib Accelerated Approval to Treat CLL/SLL in the Third LineFDA Approves Eflornithine for Children, Adults With High-Risk NeuroblastomaFDA Approves Belzutifan for Patients With Advanced Renal Cell CarcinomaEnfortumab Vedotin Plus Pembrolizumab Snags Full Approval for Patients With Locally ...
    Show More Show Less
    10 mins
  • S5 Ep79: Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

    S5 Ep79: Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
    Dec 14 2023
    In this episode of The Vitals, Beth Finley-Oliver, MSN, ARNP, AGNP-BC, a nurse practitioner who works in the outpatient hematology clinic at Moffitt Cancer Center, revisits her presentation from the 2023 JADPRO Live Annual Meeting and discusses the growing number of therapies for patients with relapsed or refractory multiple myeloma.

    Episode Highlights
    “A clinical trial upfront would be my first option. After that, I have to try and find something their myeloma hasn't seen yet.”

    “With CAR T, the CRS incidence is higher, and I think we're doing better [at managing it] because we have multiple interventions. We see viral infections with [both] the CAR T and the bispecifics. We always have to kind of keep that in the back of our mind.”

    “The more medications we have, the more this is turning into a chronic illness.”

     For More On Multiple Myeloma:

    • Delivering Teclistamab in the Outpatient Setting
    • Ambulation Improves Frailty Scores in Patients With Multiple Myeloma
    • With New Bispecific Antibodies in Multiple Myeloma, Nurses Need To Know How to Manage CRS


    Video Interviews

    • Managing Teclistamab-Induced CRS for Patients With Multiple Myeloma
    • Data Supporting Elranatamab Approval in Multiple Myeloma
    • Data Behind Talquetamab Approval in Multiple Myeloma

    More Podcast Episodes

    • Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape
    • ASH Data Offer Treatment Direction for Oncology Nursing Professionals
    • A Look Back at 2022 FDA Approvals in Oncology
    • Conversations Around Selinexor: Best Nursing Practices in Multiple Myeloma
    Show More Show Less
    11 mins
  • S5 Ep78: Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

    S5 Ep78: Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL
    Dec 1 2023
    In May 2023, the FDA granted accelerated approval to epcoritamab-bysp (Epkinly) for the treatment of adult patients with relapsed/refractory (R/R) DLBCL, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma (HGBL), following 2 or more lines of systemic therapies. Shortly thereafter, in June 2023, the FDA granted accelerated approval to glofitamab-gxbm (Columvi) as a fixed duration treatment for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after 2 or more lines of systemic therapy.  In this episode of The Vitals, Laura Zitella, MS, RN, ACNP-BC, AOCN, who is a hematology nurse practitioner in the Hematology, Blood, Marrow transplant, and Cellular Therapy (HBC) program at UCSF Health and associate clinical professor in the Department of Physiological Nursing at the University of California San Francisco, joins Oncology Nursing News to discuss how these newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.   Episode Highlights “Bispecific antibodies are antibodies that generally have at least 2 antigen binding sites: 1 binding site is to the antigen of interest on the cancer cell, and in lymphoma, that's often CD19, or CD20. The other antigen binding site is to CD3, which is a T-cell marker.” “Unfortunately, we do not cure all patients with second-line therapy [and] the bispecifics are used for third-line therapy, where we have historically had limited treatment options.” “One of the big advantages of bispecific antibodies is that they are ‘off-the-shelf;’ they do not need to be manufactured, and they are available immediately." “Epcoratimab is a subcutaneous [administration] bispecific antibody, whereas glofitamab is an intravenous [administration]. Both require step-up dosing, which means that you start with a small dose and then the subsequent doses are a little bit higher, and a little bit higher until you reach your treatment dose.” For More on DLBCL Glofitamab Gains Accelerated Approval for Relapsed/Refractory DLBCLEpcoritamab Obtains Accelerated Approval for Relapsed/Refractory DLBCLInvestigators Unveil Real-World Experiences on Shared Decision-Making in R/R DLBCL For More On Bispecific Antibodies With New Bispecific Antibodies in Multiple Myeloma, Nurses Need To Know How to Manage CRSNovel Immune Checkpoint Inhibitors, Bispecific Antibodies Become Clinical Mainstays in Melanoma NursingSmith Discusses Evolving Landscape of Lymphoma TreatmentsBispecific Antibodies May Change Lung Cancer Paradigm More Podcast Episodes in Hematology  Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment LandscapeOncology Nursing Stories: Off-The-Shelf CAR T Therapy for Acute Lymphoblastic LeukemiaOncology Nursing Stories: Pregnancy After Lymphoma ChemoradiationConversations Around Selinexor: Best Nursing Practices in Multiple MyelomaStephanie Jackson Unpacks Recent Advances in Leukemia Treatments
    Show More Show Less
    11 mins

What listeners say about Oncology Nursing News: The Vitals

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.